Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.17
NYSE:A's Cash to Debt is ranked lower than
58% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NYSE:A: 1.17 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:A' s Cash to Debt Range Over the Past 10 Years
Min: 0.63  Med: 1.33 Max: No Debt
Current: 1.17
Equity to Asset 0.56
NYSE:A's Equity to Asset is ranked lower than
54% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NYSE:A: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:A' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.71
Current: 0.56
0.31
0.71
Interest Coverage 8.52
NYSE:A's Interest Coverage is ranked lower than
75% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NYSE:A: 8.52 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 7.04 Max: 12.45
Current: 8.52
0.53
12.45
F-Score: 7
Z-Score: 4.92
M-Score: -2.64
WACC vs ROIC
10.41%
13.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.25
NYSE:A's Operating margin (%) is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NYSE:A: 14.25 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:A' s Operating margin (%) Range Over the Past 10 Years
Min: 1.05  Med: 11.34 Max: 16.32
Current: 14.25
1.05
16.32
Net-margin (%) 11.66
NYSE:A's Net-margin (%) is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NYSE:A: 11.66 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:A' s Net-margin (%) Range Over the Past 10 Years
Min: -0.69  Med: 11.89 Max: 66.5
Current: 11.66
-0.69
66.5
ROE (%) 11.55
NYSE:A's ROE (%) is ranked higher than
76% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. NYSE:A: 11.55 )
Ranked among companies with meaningful ROE (%) only.
NYSE:A' s ROE (%) Range Over the Past 10 Years
Min: -1.22  Med: 21.2 Max: 85.57
Current: 11.55
-1.22
85.57
ROA (%) 6.43
NYSE:A's ROA (%) is ranked higher than
75% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NYSE:A: 6.43 )
Ranked among companies with meaningful ROA (%) only.
NYSE:A' s ROA (%) Range Over the Past 10 Years
Min: -0.42  Med: 8.23 Max: 46.84
Current: 6.43
-0.42
46.84
ROC (Joel Greenblatt) (%) 52.68
NYSE:A's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NYSE:A: 52.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:A' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.79  Med: 52.06 Max: 84.13
Current: 52.68
7.79
84.13
Revenue Growth (3Y)(%) 3.50
NYSE:A's Revenue Growth (3Y)(%) is ranked lower than
52% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NYSE:A: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:A' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: 4.8 Max: 18.4
Current: 3.5
-22.9
18.4
EBITDA Growth (3Y)(%) -4.30
NYSE:A's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NYSE:A: -4.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:A' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.7  Med: 9.7 Max: 76.6
Current: -4.3
-27.7
76.6
EPS Growth (3Y)(%) -37.70
NYSE:A's EPS Growth (3Y)(%) is ranked lower than
87% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NYSE:A: -37.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:A' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.7  Med: 11.2 Max: 135.6
Current: -37.7
-37.7
135.6
» NYSE:A's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

A Guru Trades in Q3 2015

RS Investment Management 1,301,270 sh (New)
Andreas Halvorsen 218,650 sh (New)
Louis Moore Bacon 60,000 sh (New)
Larry Robbins 4,585,170 sh (New)
Joel Greenblatt 400,556 sh (+77.32%)
Vanguard Health Care Fund 8,001,210 sh (+19.77%)
Mario Gabelli 174,800 sh (+4.86%)
Jim Simons Sold Out
Chris Davis 69,007 sh (-3.09%)
Keeley Asset Management Corp 162,000 sh (-3.65%)
PRIMECAP Management 5,165,865 sh (-9.78%)
Ron Baron 23,000 sh (-20.42%)
Paul Tudor Jones 79,252 sh (-29.81%)
Jeremy Grantham 13,800 sh (-86.89%)
» More
Q4 2015

A Guru Trades in Q4 2015

Jim Simons 48,000 sh (New)
Steven Cohen 246,200 sh (New)
Pioneer Investments 100,511 sh (New)
RS Investment Management 1,883,670 sh (+44.76%)
Mario Gabelli 184,600 sh (+5.61%)
Chris Davis 70,920 sh (+2.77%)
Ron Baron 23,000 sh (unchged)
Vanguard Health Care Fund 8,001,210 sh (unchged)
Samuel Isaly 241,000 sh (unchged)
Larry Robbins Sold Out
Jeremy Grantham Sold Out
Louis Moore Bacon Sold Out
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 5,128,870 sh (-0.72%)
Keeley Asset Management Corp 119,260 sh (-26.38%)
Paul Tudor Jones 25,047 sh (-68.40%)
» More
Q1 2016

A Guru Trades in Q1 2016

Joel Greenblatt 11,573 sh (New)
George Soros 42,800 sh (New)
Jim Simons 755,200 sh (+1473.33%)
Paul Tudor Jones 39,291 sh (+56.87%)
RS Investment Management 2,660,326 sh (+41.23%)
Mario Gabelli 202,300 sh (+9.59%)
Pioneer Investments 107,767 sh (+7.22%)
Chris Davis 72,389 sh (+2.07%)
PRIMECAP Management 5,172,590 sh (+0.85%)
Ron Baron 23,000 sh (unchged)
Keeley Asset Management Corp 105,819 sh (-11.27%)
Vanguard Health Care Fund 3,662,850 sh (-54.22%)
Steven Cohen 48,400 sh (-80.34%)
Samuel Isaly 125,000 sh (-48.13%)
» More
Q2 2016

A Guru Trades in Q2 2016

Stanley Druckenmiller 220,300 sh (New)
Columbia Wanger 883,642 sh (New)
Joel Greenblatt 171,934 sh (+1385.65%)
Ron Baron 28,000 sh (+21.74%)
Steven Cohen 52,100 sh (+7.64%)
Pioneer Investments 107,767 sh (unchged)
Samuel Isaly 125,000 sh (unchged)
George Soros Sold Out
Chris Davis Sold Out
PRIMECAP Management 5,018,630 sh (-2.98%)
Vanguard Health Care Fund 3,231,150 sh (-11.79%)
Mario Gabelli 172,400 sh (-14.78%)
RS Investment Management 2,149,542 sh (-19.20%)
Jim Simons 419,000 sh (-44.52%)
Paul Tudor Jones 9,330 sh (-76.25%)
Keeley Asset Management Corp 21,500 sh (-79.68%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:LH, OTCPK:SSMXY, NYSE:DGX, NAS:IDXX, NYSE:Q, NAS:DXCM, OTCPK:ERFSF, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:PRAH, OTCPK:CZMWY » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets. In November 2014, the Company announced a change in organizational structure designed to serve its customers. Its life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business combined to form a new segment called life sciences and applied markets business. Its diagnostics and genomics businesses combined with the nucleic acid solutions division from its life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses previously part of the life sciences and chemical analysis businesses. The Company's life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The diagnostics and genomics business is comprised of three areas of activity providing solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. In addition it conducts centralized order fulfillment and supply chain operations for businesses through the order fulfillment and supply chain organization (OFS). OFS provides resources for manufacturing, engineering and strategic sourcing to the Company's respective businesses. The life sciences and applied markets business focuses on The Pharmaceutical, Biotechnology, CRO & CMO Market; The Life Science Research Market; The Chemical & Energy Market; The Environmental & Forensics Market; and the Food Market. Its products fall into nine areas of work: liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, software and informatics, lab automation and robotics, automated electrophoresis and microfluidics, vacuum technology and nuclear magnetic resonance systems. The diagnostics and genomics business includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid contract manufacturing businesses. The segment focuses on The Diagnostics and Clinical Market. The products under the segment fall into six areas of work: pathology products, specific proteins and flow reagents, target enrichment, cytogenetic research solutions and microarrays, PCR and qPCR instrumentat

Ratios

vs
industry
vs
history
P/E(ttm) 32.56
A's P/E(ttm) is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. A: 32.56 )
Ranked among companies with meaningful P/E(ttm) only.
A' s P/E(ttm) Range Over the Past 10 Years
Min: 2.75  Med: 14.85 Max: 48.52
Current: 32.56
2.75
48.52
Forward P/E 21.69
A's Forward P/E is ranked higher than
55% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. A: 21.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.56
A's PE(NRI) is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. A: 32.56 )
Ranked among companies with meaningful PE(NRI) only.
A' s PE(NRI) Range Over the Past 10 Years
Min: 5.2  Med: 14.98 Max: 301.43
Current: 32.56
5.2
301.43
Price/Owner Earnings (ttm) 28.39
A's Price/Owner Earnings (ttm) is ranked higher than
57% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. A: 28.39 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
A' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.5  Med: 15.35 Max: 247.44
Current: 28.39
2.5
247.44
P/B 3.53
A's P/B is ranked higher than
50% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. A: 3.53 )
Ranked among companies with meaningful P/B only.
A' s P/B Range Over the Past 10 Years
Min: 1.22  Med: 2.59 Max: 3.61
Current: 3.53
1.22
3.61
P/S 3.77
A's P/S is ranked lower than
55% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. A: 3.77 )
Ranked among companies with meaningful P/S only.
A' s P/S Range Over the Past 10 Years
Min: 0.6  Med: 1.89 Max: 3.86
Current: 3.77
0.6
3.86
PFCF 22.85
A's PFCF is ranked higher than
54% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. A: 22.85 )
Ranked among companies with meaningful PFCF only.
A' s PFCF Range Over the Past 10 Years
Min: 5.46  Med: 15.36 Max: 74.96
Current: 22.85
5.46
74.96
POCF 19.56
A's POCF is ranked lower than
53% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. A: 19.56 )
Ranked among companies with meaningful POCF only.
A' s POCF Range Over the Past 10 Years
Min: 4.36  Med: 12.55 Max: 41.4
Current: 19.56
4.36
41.4
EV-to-EBIT 24.79
A's EV-to-EBIT is ranked lower than
59% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. A: 24.79 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 13.7 Max: 85.3
Current: 24.79
4.9
85.3
EV-to-EBITDA 17.52
A's EV-to-EBITDA is ranked higher than
50% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. A: 17.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 10.25 Max: 31.5
Current: 17.52
4
31.5
PEG 1.15
A's PEG is ranked higher than
84% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 1.15 )
Ranked among companies with meaningful PEG only.
A' s PEG Range Over the Past 10 Years
Min: 0.08  Med: 1.45 Max: 9.92
Current: 1.15
0.08
9.92
Shiller P/E 24.80
A's Shiller P/E is ranked higher than
79% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. A: 24.80 )
Ranked among companies with meaningful Shiller P/E only.
A' s Shiller P/E Range Over the Past 10 Years
Min: 9.95  Med: 18.78 Max: 46.42
Current: 24.8
9.95
46.42
Current Ratio 3.07
A's Current Ratio is ranked higher than
61% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. A: 3.07 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.55 Max: 4.08
Current: 3.07
1.61
4.08
Quick Ratio 2.60
A's Quick Ratio is ranked higher than
59% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. A: 2.60 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.03 Max: 3.44
Current: 2.6
1.04
3.44
Days Inventory 100.84
A's Days Inventory is ranked lower than
55% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. A: 100.84 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.78 Max: 116.91
Current: 100.84
91.25
116.91
Days Sales Outstanding 52.19
A's Days Sales Outstanding is ranked higher than
62% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. A: 52.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 49.31 Max: 58.26
Current: 52.19
47.45
58.26
Days Payable 48.07
A's Days Payable is ranked lower than
60% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. A: 48.07 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.18 Max: 72.45
Current: 48.07
43.61
72.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.94
A's Dividend Yield is ranked lower than
58% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. A: 0.94 )
Ranked among companies with meaningful Dividend Yield only.
A' s Dividend Yield Range Over the Past 10 Years
Min: 0.31  Med: 1.17 Max: 1.42
Current: 0.94
0.31
1.42
Dividend Payout 0.31
A's Dividend Payout is ranked higher than
63% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. A: 0.31 )
Ranked among companies with meaningful Dividend Payout only.
A' s Dividend Payout Range Over the Past 10 Years
Min: 0.08  Med: 0.3 Max: 4.4
Current: 0.31
0.08
4.4
Forward Dividend Yield 0.97
A's Forward Dividend Yield is ranked lower than
62% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. A: 0.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.95
A's Yield on cost (5-Year) is ranked lower than
63% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. A: 0.95 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
A' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.31  Med: 1.17 Max: 1.42
Current: 0.95
0.31
1.42
3-Year Average Share Buyback Ratio 1.20
A's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. A: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 0.75 Max: 11.4
Current: 1.2
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 109.72
A's Price/Net Current Asset Value is ranked lower than
97% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. A: 109.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
A' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.8  Med: 11.41 Max: 1364
Current: 109.72
2.8
1364
Price/Tangible Book 11.15
A's Price/Tangible Book is ranked lower than
76% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. A: 11.15 )
Ranked among companies with meaningful Price/Tangible Book only.
A' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.1  Med: 3.84 Max: 12.49
Current: 11.15
1.1
12.49
Price/Projected FCF 1.40
A's Price/Projected FCF is ranked higher than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. A: 1.40 )
Ranked among companies with meaningful Price/Projected FCF only.
A' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.18 Max: 3.07
Current: 1.4
0.61
3.07
Price/DCF (Earnings Based) 3.04
A's Price/DCF (Earnings Based) is ranked lower than
82% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. A: 3.04 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.00
A's Price/Median PS Value is ranked lower than
87% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. A: 2.00 )
Ranked among companies with meaningful Price/Median PS Value only.
A' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 0.93 Max: 2.04
Current: 2
0.38
2.04
Price/Graham Number 4.02
A's Price/Graham Number is ranked lower than
58% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. A: 4.02 )
Ranked among companies with meaningful Price/Graham Number only.
A' s Price/Graham Number Range Over the Past 10 Years
Min: 0.84  Med: 1.96 Max: 9.54
Current: 4.02
0.84
9.54
Earnings Yield (Greenblatt) (%) 4.03
A's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. A: 4.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
A' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 7.3 Max: 20.2
Current: 4.03
1.2
20.2
Forward Rate of Return (Yacktman) (%) -6.16
A's Forward Rate of Return (Yacktman) (%) is ranked lower than
81% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. A: -6.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
A' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.3  Med: 11.9 Max: 78.6
Current: -6.16
-6.3
78.6

More Statistics

Revenue (TTM) (Mil) $4,126
EPS (TTM) $ 1.45
Beta1.34
Short Percentage of Float1.27%
52-Week Range $33.12 - 48.63
Shares Outstanding (Mil)324.38

Analyst Estimate

Oct16 Oct17 Oct18
Revenue (Mil $) 4,152 4,350 4,529
EPS ($) 1.86 2.17 2.42
EPS w/o NRI ($) 1.86 2.17 2.42
EPS Growth Rate
(3Y to 5Y Estimate)
11.33%
Dividends Per Share ($) 0.47 0.52 0.47
» More Articles for NYSE:A

Headlines

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
Agilent, Apple and Canadian Pacific Are Among Larry Robbins' New Buys Dec 22 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Larry Robbins Buys Cigna, Monsanto and Sells Out McDonald's Dec 09 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 
Garmin: A Bargain for Patient Investors Apr 30 2015 
Weekly 52-Week Highs Highlight: ADS, CHT, A, KYO, LFC Apr 12 2015 
Agilent Has Focused on Several Strategic Actions Mar 20 2014 

More From Other Websites
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics Sep 28 2016
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics Sep 28 2016
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Sep 22 2016
Agilent Technologies Launches New Panel for Fast FISH Testing Sep 22 2016
Agilent Technologies Launches New Panel for Fast FISH Testing on Dako Omnis in Lung Cancer Sep 22 2016
Agilent Technologies Announces Cash Dividend of 11.5 Cents per Share Sep 21 2016
Agilent Technologies Announces Cash Dividend of 11.5 Cents Per Share Sep 21 2016
Agilent Senior Notes Get Moody's Baa2 Rating; Outlook Stable Sep 21 2016
ETF’s with exposure to Agilent Technologies, Inc. : September 19, 2016 Sep 19 2016
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Sep 16 2016
Agilent (A) Prices $300M Senior Notes in Public Offering Sep 16 2016
Agilent Technologies Prices $300 Million of Senior Notes Sep 15 2016
Agilent Technologies Prices $300 Million of Senior Notes Sep 15 2016
Agilent Technologies Announces Offering of Senior Notes Sep 15 2016
Agilent Technologies Announces Offering of Senior Notes Sep 15 2016
Northcoast Research Upgrades Thor Industries to a ‘Buy’ Sep 14 2016
AGILENT TECHNOLOGIES INC Financials Sep 13 2016
Agilent Technologies Lowers the Cost of Multi-Element Analysis Sep 13 2016
Agilent Technologies Lowers the Cost of Multi-Element Analysis Sep 13 2016
BDNA to Discuss How to Deflect Vendor Audits at 2016 Gartner IT Financial, Procurement & Asset... Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)